Manuso, Ph.D., President, Chief Executive Officer and Vice Chairman stated, “We are very excited with the possibility of bringing to market the first drug treatment for OSA. We can now envision a small molecule, easy to use, oral medicine for OSA patients as an alternative to CPAP (continuous positive airway pressure) devices, surgery and other methods used to treat this underappreciated disease, which has such enourmous costs to society.” “We look forward to discussing with investors the results of this trial at upcoming conferences.” Background Obstructive Sleep Apnea is the most common form of sleep apnea and affects 29.4 million Americans according to Frost & Sullivan. 5.9 million adults are diagnosed (23.5 million are undiagnosed).OSA, besides causing next day sleepiness which is a major cause of motor vehicle and industrial accidents, is also co-morbid with cardiovascular disease, type 2 diabetes and other conditions.Treatment options are limited and the most effective treatment, the CPAP device has an extremely high non-compliance rate. The overall cost to the U.S. economy of the diagnosed and undiagnosed portions of the OSA market are estimated to be $12.4 billion and $149.6 billion respectively for a total cost of $162.0 billion in 2015. There is no drug therapy approved for OSA.While certain stimulants such as modafinil and methylphenidate are FDA approved for next day sleepiness in certain OSA patients, they do not treat OSA itself.Dronabinol, currently formulated as a capsule, is believed to be much more user friendly than the current devices, should have a higher patient compliance rate, should work well in the moderate to mild patient segment, which represents approximately 50% of the overall OSA patient population, and may result in more of the currently undiagnosed patient population getting diagnosed. Read More Dronabinol is synthetic 9-THC (delta 9-tetrahydrocannabinol), one of the active cannabinoids found in marijuana.It is approved in the United States in 2.5mg, 5mg and 10mg capsules for the treatment of anorexia associated with AIDS and chemo-therapy induced nausea and vomiting.It is a schedule III drug meaning there is a low abuse potential, but it is monitored by the United States DEA (drug enforcement agency). It is Medicare part B reimbursed for its current approved indications. Use of dronabinol for the treatment of OSA is novel. About RespireRx Pharmaceuticals Inc.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/respirerx-pharmaceuticals-inc-announces-positive-130000109.html
“Before competition for me would be like a chicken breast and maybe a little pasta. The carbs help because you’re going out and playing a lot of minutes,” James told Business Insider. “But a salad and some veggies will have me perfectly fine. And before the game I might have a protein shake and some fruit, and I’ll be ready to go.But as far as pies or pizza and sandwiches and french fries I can’t. I’ll wait for that after the game. I can’t do that before the game.” official sourceAs for his workout schedule, James says he works out about 5 days a week in the off-season and 7 days per week when basketball starts back up. James likes to mix up the way he exercises and throws in a few classes on top of traditional gym workouts. “My workout regimen is pretty much five times a week, every day. And it varies,” James told Business Insider. “Sometimes I stay at home and work out. Sometimes I’ll go to an actual class.
For the original version including any supplementary images or video, visit http://www.businessinsider.com/lebron-james-eats-diet-workout-routine-2016-12?utm_source=feedburner&utm_medium=referral
Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome Ann C. Increased discover ability of research and high quality peer review are ensured by on-line links to the sources cited. Soriano | David B. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. HF coexists in more than 20% of patients with cod, and is associated with early readmission for cod. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in cod: Results from the ECLIPSE study Vasileios Andrianopoulos | Bartolome R. Essential title page information • Title. http://fc.cx/medicalinterviewcourse96026The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Ensure that all equipment is functional, clean, and free from pathogenic organisms 5. The CONSORT check-list and template flow diagram are available on-line.